Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases

JCO Precis Oncol. 2023 Sep:7:e2300451. doi: 10.1200/PO.23.00451.

Abstract

Two cases show osimertinib/sotorasib combination could be effective in KRAS G12C-driven osimertinib resistance.

Publication types

  • Case Reports

MeSH terms

  • Humans
  • Mutation
  • Proto-Oncogene Proteins p21(ras)* / genetics

Substances

  • osimertinib
  • sotorasib
  • Proto-Oncogene Proteins p21(ras)
  • KRAS protein, human